How has been the historical performance of Epigral?

Answer:The historical performance of Epigral shows significant growth in key financial metrics over the past five years.

Breakdown:
Epigral's net sales have increased from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, demonstrating a strong upward trend. Total operating income followed a similar trajectory, rising from 828.60 Cr to 2,550.13 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 567.28 Cr in Mar'21 to 1,839.41 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) has shown fluctuations, peaking at 725.93 Cr in Mar'25, while profit before tax reached 540.10 Cr, up from 160.86 Cr in Mar'21. Profit after tax has also risen significantly, from 100.84 Cr in Mar'21 to 356.70 Cr in Mar'25. The earnings per share (EPS) increased from 24.27 in Mar'21 to 82.91 in Mar'25, indicating improved profitability per share. On the balance sheet, total assets grew from 1,448.70 Cr in Mar'21 to 3,152.44 Cr in Mar'25, while total liabilities increased from 1,448.70 Cr to 3,152.44 Cr, showing a proportional rise in both assets and liabilities. Cash flow from operating activities improved from 229.00 Cr in Mar'21 to 440.00 Cr in Mar'25, contributing to a net cash inflow of 15.00 Cr in Mar'25, compared to an outflow of 11.00 Cr in Mar'24. Overall, Epigral has demonstrated robust growth in sales, profits, and asset base over the past five years.